(Reuters) -AstraZeneca said on Monday it would pay up to $1.92 billion to CSPC Pharmaceutical Group Ltd in an exclusive licence agreement to boost the Anglo-Swedish drugmaker's cardiovascular pipeline ...

On Monday, AstraZeneca plc (NASDAQ:AZN) entered into an exclusive license agreement with Hong Kong-based CSPC Pharmaceutical Group Ltd to advance the development of an early-stage, novel ...

(Reuters) -AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for ...

AstraZeneca has licensed a small-molecule lipoprotein disruptor from China’s CSPC Pharmaceutical Group for $100 million. The molecule is intended to prevent formation of lipoprotein(a), high ...

AstraZeneca PLC (NASDAQ:AZN) is one of the 11 Best Strong Buy Stocks to Invest in Now. On June 13, AstraZeneca PLC (NASDAQ:AZN) announced that it had entered into a strategic research collaboration ...

AstraZeneca (NASDAQ:AZN) is looking to boost its cardiovascular pipeline through an exclusive license agreement with CSPC Pharmaceutical Group (CSPC). As part of the deal, AstraZeneca will pay $100M ...

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Friday that it has entered into a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Lts, ...

Astrazeneca plc is adding a preclinical-stage candidate to its cardiovascular pipeline via a potentially $2 billion licensing agreement with CSPC Pharmaceutical Group Ltd., which includes a $100 ...

Cardiovascular disease drugs in development intended to reduce lipoprotein (a) are mostly injectable medications, though Eli Lilly has both oral and injectable drugs in the clinic. AstraZeneca aims to ...

AstraZeneca PLC (NASDAQ:AZN) is one of the 11 Best Strong Buy Stocks to Invest in Now. On June 13, AstraZeneca PLC (NASDAQ:AZN) announced that it had entered into a strategic research collaboration ...